Condition: Prostate Cancer Metastatic · Prostate Cancer · CRPC · Sponsor: Washington D.C. Veterans Affairs Medical Center
Use of Enhertu as a Subsequent Line of Therapy in HER2-Positive Metastatic Castration-Resistant Prostate Adenocarcinoma.
This description comes directly from the study's public registry record.
Asha Escobar · 2027431090 · asha.escobar@va.gov
Martha Antonio · martha.antonio@va.gov
Always discuss trial participation with your own doctor first.
| Washington DC VAMC | Washington D.C., District of Columbia, United States | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06610825